šŸ’‰ Hims & Hers Cashes In

+ Meta Launches Standalone AI App to Compete With ChatGPT

Good afternoon! Caesars is cashing in where it counts—and it’s not the roulette tables. Shares popped nearly 14% last week after the casino giant dropped a new NBA-themed slot game just as the playoffs heat up. Digital gambling has become Caesars’ MVP, raking in $1.1 billion last year while Vegas revenues keep cooling.

Now, the company’s online empire is growing so fast there’s talk of spinning it off. With brick-and-mortar casinos losing steam, Caesars is betting its future on your phone screen—and so far, it’s hitting nothing but net.

MARKETS

*Stock data as of market close*

  • Markets ended solidly in the green Tuesday after a choppy start, with earnings season in full swing and automakers scoring a temporary break from tariffs. The Dow climbed 300 points (0.75%), while the S&P 500 rose 0.58% and the Nasdaq added 0.55%—marking the longest win streak of the year for the Dow and S&P.

  • Fueling the optimism: whispers of a major trade deal on the horizon. The White House teased progress without naming names, and Treasury Secretary Scott Bessent kept the pressure on China, saying ā€œthe onus is on them.ā€ Investors don’t have details, but they liked the sound of less trade drama.

STOCKS
Winners & Losers

What’s up šŸ“ˆ

  • Leggett & Platt soared 31.6% after the bedding products manufacturer reiterated its full-year outlook. ($LEG)

  • Hims & Hers Health jumped 23% following news that Novo Nordisk will offer its weight loss drug Wegovy through Hims’ platform. ($HIMS)

  • Cadence Design Systems advanced 5.7% after posting first-quarter earnings of $1.57 per share, surpassing estimates. ($CDNS)

  • Honeywell rallied 5.4% on better-than-expected earnings for the first quarter. ($HON)

  • Deutsche Bank jumped 4% as the lender saw its profit surge 39% in the first quarter. ($DB)

  • Sherwin-Williams advanced 4.8% after better-than-expected earnings per share and reaffirmed full-year guidance. ($SHW)

  • Pfizer popped 3.2% after announcing an expansion of its cost-cutting initiatives and posting a profit that surpassed expectations. ($PFE)

  • D.R. Horton rose 3.16% despite weaker-than-expected Q2 earnings, as investors remained bullish on housing. ($DHI)

What’s down šŸ“‰

  • NXP Semiconductors tumbled 6.94% after lower-than-expected earnings guidance disappointed investors. ($NXPI)

  • Regeneron slid 6.87% due to disappointing sales for its eye drug Eylea. ($REGN)

  • Wolfspeed declined 15.98% after a short squeeze rally fizzled out. ($WOLF)

  • Spotify dropped 3.48% even with active monthly users rising 10%, as lower guidance hurt investor sentiment. ($SPOT)

TELEHEALTH
Hims & Hers to Sell Novo Nordisk’s Wegovy in U.S.

Hims & Hers just made a comeback worthy of a Netflix docuseries. Novo Nordisk, maker of the hit weight-loss drug Wegovy, is now letting Hims, Ro, and LifeMD sell the injectable directly to customers at a discounted price—starting as low as $499/month. That’s about 60% off the sticker price, and it comes bundled with clinical support and wellness coaching.

A Sudden Alliance

Until recently, these telehealth firms were Novo’s biggest headache—hawking cheaper, compounded versions of GLP-1s while the real thing was stuck in shortage limbo. But with the FDA cracking down on compounded meds and insurance coverage still iffy, Novo’s strategy has flipped: if you can’t beat the DTC platforms, join ā€˜em.

Market Reacts: Injected with Optimism

Wall Street loved the pivot. Hims shares spiked 33%, LifeMD soared 41%, and Novo ticked up 4%. The move mirrors Eli Lilly’s recent link-up with WeightWatchers to push its own drug, Zepbound, in a race to dominate the obesity drug market—which analysts expect could top $100 billion.

The New Weight-Loss Pipeline: Telehealth platforms are becoming the new front door for blockbuster drugs. And with pill-based versions of GLP-1s on the horizon, expect even more shakeups ahead. In the meantime, Wegovy’s gone from pharmacy counter to subscription box—and Hims just went from underdog to golden child.

NEWS
Market Movements

AI
Meta Launches Standalone AI App to Compete With ChatGPT

Meta dropped a standalone AI app on Tuesday, making it easier for users to access Meta AI without diving into Instagram, WhatsApp, or Facebook. Powered by Meta’s Llama 4 model, the app lets you chat, ask questions, and even hold voice conversations—basically trying to do everything ChatGPT can, but with a heavy dose of personalization based on all the data you’ve already shared with Meta.

What Makes It Different

Unlike OpenAI or Anthropic, Meta doesn’t have to guess what you like—it already knows. The new app taps into your existing profile info, your favorite posts, and your friend list to serve up more customized answers. If you want, you can even teach it extra facts about you, like being lactose intolerant, so it doesn't recommend a cheese tasting on your next trip. (Yes, really.)

Trying to Be Social, Too

Meta’s AI app also features a ā€œDiscoverā€ feed where users can post about how they’re using AI—like asking the bot to describe them in three emojis. Sharing is optional, but it’s clear Meta hopes to make AI a little more viral and a lot more social. Just remember: Meta’s empire is built on ads, so you might want to double-check what you’re sharing with your new AI pal.

Big Picture: The move shows how seriously Meta is gunning for ChatGPT and the broader consumer AI market, joining a growing pileup of AI apps from Google, xAI, and others. Meta says it’s already serving 700 million monthly users across its platforms and expects that number to top a billion by the end of the year. For now, Meta’s strategy is simple: If you’re already living inside its apps, why not make it your go-to AI, too?

Calendar
On The Horizon

Tomorrow

Wall Street’s bracing for a data deluge tomorrow, with key reports set to test investor nerves. First up: first-quarter GDP, which could show early signs of tariff fallout, plus the ADP jobs report ahead of Friday’s big labor print. March’s PCE inflation data will also drop, giving the Fed one last inflation gut check before tariffs muddy the waters even more.

As if that’s not enough, a parade of earnings is on deck. Heavyweights like Samsung, Qualcomm, Caterpillar, Airbus, Robinhood, and Wingstop are all set to report, making tomorrow a true stress test for stocks across tech, industrials, and consumer names.

NEWS
The Daily Rundown

REFERRAL
Share Investinq šŸ¤ Acquire Swag

If you love reading our newsletter, don’t be selfish — share it. Odds are your favorite finance bro, trader, investor, or stock market fanatic will too.

Don’t keep all the market news to yourself — share the love using the unique link below.

We deliver you all the news for free every single day (go on… help us out ;)

And here’s the kicker: every referral you make gets you entered into a raffle to win some awesome prizes listed below. Just share the link below and you’ll be entered once they sign up.

RESOURCES
The Federal Reserve Resource

Join our small yet growing subreddit šŸš€: https://www.reddit.com/r/investinq/

Wall Street Reads šŸ’Ž (Best Books):

Check out our latest issues šŸŽÆ: https://investinq.beehiiv.com